Oak Semaglutide Review

Oak—found at oaklovesyou.com under the Oak Longevity brand—is a newer cash-pay GLP-1 telehealth service whose pitch is pricing simplicity: one price at every dosage, no subscription, no membership fees. Our research (checked July 25, 2026) verified genuinely consumer-friendly pricing mechanics alongside a thin early record and company details that need clarifying before you pay.

The Flat-Price, No-Subscription Model

Verified from Oak's pages as of July 2026:

• Compounded semaglutide—as low as $119/month (independent coverage cites ~$130 depending on plan)
• Compounded tirzepatide—as low as $185/month (~$199 per independent coverage)
• $200 new-patient offer advertised; free shipping and free health coaching on every plan
• Also offered: NAD+, glutathione, tadalafil, and sermorelin peptides

Two mechanics stand out favorably: the price stays flat across all dosages (no titration price creep), and Oak advertises "no subscriptions"—you're not locked into auto-renewal by default, which sidesteps the cancellation-friction complaints that plague much of this category. Approval is same-day with no video call required—convenient, though questionnaire-only prescribing puts the screening weight on your honest intake.

What to Clarify Before Paying

Oak's public pages carry a phone number (435-244-7757) and a LegitScript badge, but no physical address, no email, no named physicians, no named pharmacies (just "licensed U.S. compounding pharmacies"), and no published refund policy. Its legal footer references multiple entities—Oak Longevity Holdings Corp., Flow Longevity Holdings Corp., and Mito Health Holdings Corp.—an unexplained structure worth a direct question. Its self-reported patient counts are also inconsistent ("10,000+ satisfied patients" and "trusted by 5,000+ members" appear on the same site). None of this is disqualifying for a 2026-launched brand, but ask: which entity bills you, which pharmacy fills your prescription, and what the refund terms are—in writing.

Early Independent Record

Oak's Trustpilot profile is real but thin: roughly 4.0 stars across about 46 reviews as of July 2026. Individual reviews praise the quick application, fast delivery, pricing, and results; the volume is too small for firm conclusions in either direction. Check the live profile as it grows.

Critical 2026 Regulatory Context

In 2026 the FDA proposed excluding semaglutide and tirzepatide from the 503B bulks list, restricting mass GLP-1 compounding. Confirm current availability and sourcing before enrolling.

Important: Compounded Medications

Oak's compounded semaglutide and tirzepatide are not Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications are not FDA-approved finished drug products and have not been reviewed by the FDA for safety, effectiveness, or quality. Consult your own physician before starting.